Assoc. Prof. Serge Lyashchenko, Ph.D.
Clinical Translation of Novel Radiopharmaceuticals
Novel molecular imaging and radiotherapy agents carry the promise of offering effective treatment options for patients in whom the clinical need is currently unmet by the existing diagnostic and therapeutic modalities. Efficient introduction of these agents into first-in-human evaluations requires extensive multidisciplinary team collaboration, with radiopharmaceutical developers and clinical investigators playing a major role. The scope of the lecture will cover the radiopharmacy-related practical considerations that should be made when implementing a novel radiopharmaceutical development and clinical translation program.
Curriculum vitae
- 2024-present: Assoc. Prof. of Radiochemistry and Radiopharmacy Research, Weil Cornell Medical College, Cornell University, New York, NY
- 2020-present: Associate Attending Radiopharmacist, Memorial Sloan Kettering Cancer Center, New York, NY
- 2019-2025: Co-Founder and Senior Advisor, Evergreen Theragnostics, Inc., a nuclear medicine company
- 2019-2022: Co-Founder and Chief Scientific Officer, Evergreen Theragnostics, Inc., a nuclear medicine company.
Possessing extensive expertise as both a clinical radiopharmacist and radiopharmaceutical development scientist, Dr. Lyashchenko is responsible for the development and clinical translation of molecular imaging and radioligand therapy agents manufactured for human use. His professional focus is on the clinical development of radiolabeled antibody and peptide-based diagnostic and therapeutic agents. He also oversees the production of all radiopharmaceuticals produced by the MSK Radiochemistry and Molecular Imaging Probe Core Facility, as well as hyperpolarized MRI imaging agents produced under cGMP conditions using the Diamond Hyperpolarizer. In addition, Dr. Lyashchenko has taken a lead role in the rapidly expanding global field of radiopharmacy, with a focus on improving global patient access to radiopharmaceuticals through his collaborations with the International Atomic Energy Agency (IAEA) and the World Health Organization (WHO). Dr. Lyashchenko has overseen the clinical translation of more than 30 molecular imaging and radioligand therapy agents for oncology indications.